EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes

Anna Casu, Yury O Nunez Lopez, Gongxin Yu, Christopher Clifford, Anika Bilal, Alejandra M Petrilli, Heather Cornnell, Elvis Alvarez Carnero, Ananya Bhatheja, Karen D Corbin, Anton Iliuk, David M Maahs und 1 weitere

Frontiers in Endocrinology · 2023

DOI: 10.3389/fendo.2023.1219293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, 2023. Verfasst von Anna Casu und 12 weiteren Autor:innen. Beteiligte Einrichtung: AdventHealth, Translational Research Institute (TRI), Orlando, FL, United States. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Extracellular Vesicles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There are no validated clinical or laboratory biomarkers to identify and differentiate endotypes of type 1 diabetes (T1D) or the risk of progression to chronic complications. Extracellular vesicles (EVs) have been studied as biomarkers in several different disease states but have not been well studied in T1D.

Methods

As the initial step towards circulating biomarker identification in T1D, this pilot study aimed to provide an initial characterization of the proteomic and phosphoproteomic landscape of circulating EV-enriched preparations in participants with established T1D (N=10) and healthy normal volunteers (Controls) (N=7) (NCT03379792) carefully matched by age, race/ethnicity, sex, and BMI. EV-enriched preparations were obtained using EVtrap ® technology. Proteins were identified and quantified by LC-MS analysis. Differential abundance and coexpression network (WGCNA), and pathway enrichment analyses were implemented.

Results

The detected proteins and phosphoproteins were enriched (75%) in exosomal proteins cataloged in the ExoCarta database. A total of 181 proteins and 8 phosphoproteins were differentially abundant in participants with T1D compared to controls, including some well-known EVproteins (i.e., CD63, RAB14, BSG, LAMP2, and EZR). Enrichment analyses of differentially abundant proteins and phosphoproteins of EV-enriched preparations identified associations with neutrophil, platelet, and immune response functions, as well as prion protein aggregation. Downregulated proteins were involved in MHC class II signaling and the regulation of monocyte differentiation. Potential key roles in T1D for C1q, plasminogen, IL6ST, CD40, HLA-DQB1, HLA-DRB1, CD74, NUCB1, and SAP, are highlighted. Remarkably, WGCNA uncovered two protein modules significantly associated with pancreas size, which may be implicated in the pathogenesis of T1D. Similarly, these modules showed significant enrichment for membrane compartments, processes associated with inflammation and the immune response, and regulation of viral processes, among others.

Discussion

This study demonstrates the potential of proteomic and phosphoproteomic signatures of EV-enriched preparations to provide insight into the pathobiology of T1D. The WGCNA analysis could be a powerful tool to discriminate signatures associated with different pathobiological components of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Extracellular VesiclesHumansProteomeProteomicsPilot ProjectsBiomarkersPhosphoproteins

Stichwörter der Autor:innen

extracellular vesicleshumanphosphoproteomicsproteomicstype 1 diabetes

Substanzen

ProteomeBiomarkersPhosphoproteins

Autor:innen und Institutionen

  • AdventHealth, Translational Research Institute (TRI), Orlando, FL, United States.
  • Biomarker Discovery Department, Tymora Analytical Operations, West Lafayette, IN, United States.
  • Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Casu, A., Nunez Lopez, Y. O., Yu, G., Clifford, C., Bilal, A., Petrilli, A. M., Cornnell, H., Carnero, E. A., Bhatheja, A., Corbin, K. D., Iliuk, A., Maahs, D. M., & Pratley, R. E. (2023). The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1219293

Vancouver

Casu A, Nunez Lopez YO, Yu G, Clifford C, Bilal A, Petrilli AM, et al. The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes. Frontiers in Endocrinology. 2023. doi:10.3389/fendo.2023.1219293

BibTeX
@article{Casu2023,
  author = {Casu, Anna and Nunez Lopez, Yury O and Yu, Gongxin and Clifford, Christopher and Bilal, Anika and Petrilli, Alejandra M and Cornnell, Heather and Carnero, Elvis Alvarez and Bhatheja, Ananya and Corbin, Karen D and Iliuk, Anton and Maahs, David M and Pratley, Richard E},
  title = {The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes},
  journal = {Frontiers in Endocrinology},
  year = {2023},
  doi = {10.3389/fendo.2023.1219293}
}
Kostenlos starten →